Cargando…
Motor symptoms in genetic frontotemporal dementia: developing a new module for clinical rating scales
OBJECTIVE: To investigate the optimal method of adding motor features to a clinical rating scale for frontotemporal dementia (FTD). METHODS: Eight hundred and thirty-two participants from the international multicentre Genetic FTD Initiative (GENFI) study were recruited: 522 mutation carriers (with C...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9971048/ https://www.ncbi.nlm.nih.gov/pubmed/36385202 http://dx.doi.org/10.1007/s00415-022-11442-y |
_version_ | 1784898026199842816 |
---|---|
author | Samra, Kiran MacDougall, Amy M. Peakman, Georgia Bouzigues, Arabella Bocchetta, Martina Cash, David M. Greaves, Caroline V. Convery, Rhian S. van Swieten, John C. Jiskoot, Lize Seelaar, Harro Moreno, Fermin Sanchez-Valle, Raquel Laforce, Robert Graff, Caroline Masellis, Mario Tartaglia, Carmela Rowe, James B. Borroni, Barbara Finger, Elizabeth Synofzik, Matthis Galimberti, Daniela Vandenberghe, Rik de Mendonça, Alexandre Butler, Chris R. Gerhard, Alexander Ducharme, Simon Le Ber, Isabelle Tiraboschi, Pietro Santana, Isabel Pasquier, Florence Levin, Johannes Otto, Markus Sorbi, Sandro Rohrer, Jonathan D. Russell, Lucy L. |
author_facet | Samra, Kiran MacDougall, Amy M. Peakman, Georgia Bouzigues, Arabella Bocchetta, Martina Cash, David M. Greaves, Caroline V. Convery, Rhian S. van Swieten, John C. Jiskoot, Lize Seelaar, Harro Moreno, Fermin Sanchez-Valle, Raquel Laforce, Robert Graff, Caroline Masellis, Mario Tartaglia, Carmela Rowe, James B. Borroni, Barbara Finger, Elizabeth Synofzik, Matthis Galimberti, Daniela Vandenberghe, Rik de Mendonça, Alexandre Butler, Chris R. Gerhard, Alexander Ducharme, Simon Le Ber, Isabelle Tiraboschi, Pietro Santana, Isabel Pasquier, Florence Levin, Johannes Otto, Markus Sorbi, Sandro Rohrer, Jonathan D. Russell, Lucy L. |
author_sort | Samra, Kiran |
collection | PubMed |
description | OBJECTIVE: To investigate the optimal method of adding motor features to a clinical rating scale for frontotemporal dementia (FTD). METHODS: Eight hundred and thirty-two participants from the international multicentre Genetic FTD Initiative (GENFI) study were recruited: 522 mutation carriers (with C9orf72, GRN and MAPT mutations) and 310 mutation-negative controls. A standardised clinical questionnaire was used to assess eight motor symptoms (dysarthria, dysphagia, tremor, slowness, weakness, gait disorder, falls and functional difficulties using hands). Frequency and severity of each motor symptom was assessed, and a principal component analysis (PCA) was performed to identify how the different motor symptoms loaded together. Finally, addition of a motor component to the CDR(®) plus NACC FTLD was investigated (CDR(®) plus NACC FTLD-M). RESULTS: 24.3% of mutation carriers had motor symptoms (31.7% C9orf72, 18.8% GRN, 19.3% MAPT) compared to 6.8% of controls. Slowness and gait disorder were the commonest in all genetic groups while tremor and falls were the least frequent. Symptom severity scores were similar to equivalent physical motor examination scores. PCA revealed that all motor symptoms loaded together so a single additional motor component was added to the CDR(®) plus NACC FTLD to form the CDR(®) plus NACC FTLD-M. Individual global scores were more severe with the CDR(®) plus NACC FTLD-M, and no patients with a clinically diagnosed motor disorder (ALS/FTD-ALS or parkinsonism) were classified anymore as asymptomatic (unlike the CDR(®) plus NACC FTLD alone). CONCLUSIONS: Motor features are present in mutation carriers at all disease stages across all three genetic groups. Inclusion of motor symptoms in a rating scale that can be used in future clinical trials will not only ensure a more accurate severity measure is recorded but that a wider spectrum of FTD phenotypes can be included in the same trial. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00415-022-11442-y. |
format | Online Article Text |
id | pubmed-9971048 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-99710482023-03-01 Motor symptoms in genetic frontotemporal dementia: developing a new module for clinical rating scales Samra, Kiran MacDougall, Amy M. Peakman, Georgia Bouzigues, Arabella Bocchetta, Martina Cash, David M. Greaves, Caroline V. Convery, Rhian S. van Swieten, John C. Jiskoot, Lize Seelaar, Harro Moreno, Fermin Sanchez-Valle, Raquel Laforce, Robert Graff, Caroline Masellis, Mario Tartaglia, Carmela Rowe, James B. Borroni, Barbara Finger, Elizabeth Synofzik, Matthis Galimberti, Daniela Vandenberghe, Rik de Mendonça, Alexandre Butler, Chris R. Gerhard, Alexander Ducharme, Simon Le Ber, Isabelle Tiraboschi, Pietro Santana, Isabel Pasquier, Florence Levin, Johannes Otto, Markus Sorbi, Sandro Rohrer, Jonathan D. Russell, Lucy L. J Neurol Original Communication OBJECTIVE: To investigate the optimal method of adding motor features to a clinical rating scale for frontotemporal dementia (FTD). METHODS: Eight hundred and thirty-two participants from the international multicentre Genetic FTD Initiative (GENFI) study were recruited: 522 mutation carriers (with C9orf72, GRN and MAPT mutations) and 310 mutation-negative controls. A standardised clinical questionnaire was used to assess eight motor symptoms (dysarthria, dysphagia, tremor, slowness, weakness, gait disorder, falls and functional difficulties using hands). Frequency and severity of each motor symptom was assessed, and a principal component analysis (PCA) was performed to identify how the different motor symptoms loaded together. Finally, addition of a motor component to the CDR(®) plus NACC FTLD was investigated (CDR(®) plus NACC FTLD-M). RESULTS: 24.3% of mutation carriers had motor symptoms (31.7% C9orf72, 18.8% GRN, 19.3% MAPT) compared to 6.8% of controls. Slowness and gait disorder were the commonest in all genetic groups while tremor and falls were the least frequent. Symptom severity scores were similar to equivalent physical motor examination scores. PCA revealed that all motor symptoms loaded together so a single additional motor component was added to the CDR(®) plus NACC FTLD to form the CDR(®) plus NACC FTLD-M. Individual global scores were more severe with the CDR(®) plus NACC FTLD-M, and no patients with a clinically diagnosed motor disorder (ALS/FTD-ALS or parkinsonism) were classified anymore as asymptomatic (unlike the CDR(®) plus NACC FTLD alone). CONCLUSIONS: Motor features are present in mutation carriers at all disease stages across all three genetic groups. Inclusion of motor symptoms in a rating scale that can be used in future clinical trials will not only ensure a more accurate severity measure is recorded but that a wider spectrum of FTD phenotypes can be included in the same trial. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00415-022-11442-y. Springer Berlin Heidelberg 2022-11-17 2023 /pmc/articles/PMC9971048/ /pubmed/36385202 http://dx.doi.org/10.1007/s00415-022-11442-y Text en © Crown 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Communication Samra, Kiran MacDougall, Amy M. Peakman, Georgia Bouzigues, Arabella Bocchetta, Martina Cash, David M. Greaves, Caroline V. Convery, Rhian S. van Swieten, John C. Jiskoot, Lize Seelaar, Harro Moreno, Fermin Sanchez-Valle, Raquel Laforce, Robert Graff, Caroline Masellis, Mario Tartaglia, Carmela Rowe, James B. Borroni, Barbara Finger, Elizabeth Synofzik, Matthis Galimberti, Daniela Vandenberghe, Rik de Mendonça, Alexandre Butler, Chris R. Gerhard, Alexander Ducharme, Simon Le Ber, Isabelle Tiraboschi, Pietro Santana, Isabel Pasquier, Florence Levin, Johannes Otto, Markus Sorbi, Sandro Rohrer, Jonathan D. Russell, Lucy L. Motor symptoms in genetic frontotemporal dementia: developing a new module for clinical rating scales |
title | Motor symptoms in genetic frontotemporal dementia: developing a new module for clinical rating scales |
title_full | Motor symptoms in genetic frontotemporal dementia: developing a new module for clinical rating scales |
title_fullStr | Motor symptoms in genetic frontotemporal dementia: developing a new module for clinical rating scales |
title_full_unstemmed | Motor symptoms in genetic frontotemporal dementia: developing a new module for clinical rating scales |
title_short | Motor symptoms in genetic frontotemporal dementia: developing a new module for clinical rating scales |
title_sort | motor symptoms in genetic frontotemporal dementia: developing a new module for clinical rating scales |
topic | Original Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9971048/ https://www.ncbi.nlm.nih.gov/pubmed/36385202 http://dx.doi.org/10.1007/s00415-022-11442-y |
work_keys_str_mv | AT samrakiran motorsymptomsingeneticfrontotemporaldementiadevelopinganewmoduleforclinicalratingscales AT macdougallamym motorsymptomsingeneticfrontotemporaldementiadevelopinganewmoduleforclinicalratingscales AT peakmangeorgia motorsymptomsingeneticfrontotemporaldementiadevelopinganewmoduleforclinicalratingscales AT bouziguesarabella motorsymptomsingeneticfrontotemporaldementiadevelopinganewmoduleforclinicalratingscales AT bocchettamartina motorsymptomsingeneticfrontotemporaldementiadevelopinganewmoduleforclinicalratingscales AT cashdavidm motorsymptomsingeneticfrontotemporaldementiadevelopinganewmoduleforclinicalratingscales AT greavescarolinev motorsymptomsingeneticfrontotemporaldementiadevelopinganewmoduleforclinicalratingscales AT converyrhians motorsymptomsingeneticfrontotemporaldementiadevelopinganewmoduleforclinicalratingscales AT vanswietenjohnc motorsymptomsingeneticfrontotemporaldementiadevelopinganewmoduleforclinicalratingscales AT jiskootlize motorsymptomsingeneticfrontotemporaldementiadevelopinganewmoduleforclinicalratingscales AT seelaarharro motorsymptomsingeneticfrontotemporaldementiadevelopinganewmoduleforclinicalratingscales AT morenofermin motorsymptomsingeneticfrontotemporaldementiadevelopinganewmoduleforclinicalratingscales AT sanchezvalleraquel motorsymptomsingeneticfrontotemporaldementiadevelopinganewmoduleforclinicalratingscales AT laforcerobert motorsymptomsingeneticfrontotemporaldementiadevelopinganewmoduleforclinicalratingscales AT graffcaroline motorsymptomsingeneticfrontotemporaldementiadevelopinganewmoduleforclinicalratingscales AT masellismario motorsymptomsingeneticfrontotemporaldementiadevelopinganewmoduleforclinicalratingscales AT tartagliacarmela motorsymptomsingeneticfrontotemporaldementiadevelopinganewmoduleforclinicalratingscales AT rowejamesb motorsymptomsingeneticfrontotemporaldementiadevelopinganewmoduleforclinicalratingscales AT borronibarbara motorsymptomsingeneticfrontotemporaldementiadevelopinganewmoduleforclinicalratingscales AT fingerelizabeth motorsymptomsingeneticfrontotemporaldementiadevelopinganewmoduleforclinicalratingscales AT synofzikmatthis motorsymptomsingeneticfrontotemporaldementiadevelopinganewmoduleforclinicalratingscales AT galimbertidaniela motorsymptomsingeneticfrontotemporaldementiadevelopinganewmoduleforclinicalratingscales AT vandenbergherik motorsymptomsingeneticfrontotemporaldementiadevelopinganewmoduleforclinicalratingscales AT demendoncaalexandre motorsymptomsingeneticfrontotemporaldementiadevelopinganewmoduleforclinicalratingscales AT butlerchrisr motorsymptomsingeneticfrontotemporaldementiadevelopinganewmoduleforclinicalratingscales AT gerhardalexander motorsymptomsingeneticfrontotemporaldementiadevelopinganewmoduleforclinicalratingscales AT ducharmesimon motorsymptomsingeneticfrontotemporaldementiadevelopinganewmoduleforclinicalratingscales AT leberisabelle motorsymptomsingeneticfrontotemporaldementiadevelopinganewmoduleforclinicalratingscales AT tiraboschipietro motorsymptomsingeneticfrontotemporaldementiadevelopinganewmoduleforclinicalratingscales AT santanaisabel motorsymptomsingeneticfrontotemporaldementiadevelopinganewmoduleforclinicalratingscales AT pasquierflorence motorsymptomsingeneticfrontotemporaldementiadevelopinganewmoduleforclinicalratingscales AT levinjohannes motorsymptomsingeneticfrontotemporaldementiadevelopinganewmoduleforclinicalratingscales AT ottomarkus motorsymptomsingeneticfrontotemporaldementiadevelopinganewmoduleforclinicalratingscales AT sorbisandro motorsymptomsingeneticfrontotemporaldementiadevelopinganewmoduleforclinicalratingscales AT rohrerjonathand motorsymptomsingeneticfrontotemporaldementiadevelopinganewmoduleforclinicalratingscales AT russelllucyl motorsymptomsingeneticfrontotemporaldementiadevelopinganewmoduleforclinicalratingscales AT motorsymptomsingeneticfrontotemporaldementiadevelopinganewmoduleforclinicalratingscales |